Show simple item record

dc.contributor.authorCook, Michael
dc.contributor.authorBrown, Marc
dc.date.accessioned2018-05-25T15:56:10Z
dc.date.available2018-05-25T15:56:10Z
dc.date.issued2018-01-28
dc.identifier.citationCook , M & Brown , M 2018 , ' Polymeric gels for intravaginal drug delivery ' , Journal of Controlled Release , vol. 270 , pp. 145-157 . https://doi.org/10.1016/j.jconrel.2017.12.004
dc.identifier.issn0168-3659
dc.identifier.urihttp://hdl.handle.net/2299/20093
dc.descriptionThis document is the Accepted Manuscript version of the following article: Michael T. Cook, and Marc b. Brown, ‘Polymeric gels for intravaginal drug delivery’, Journal of Controlled Release, Vol. 270: 145-157, January 2018. Under embargo until 6 December 2018. The final, definitive version is available online at DOI: https://doi.org/10.1016/j.jconrel.2017.12.004
dc.description.abstractIntravaginal drug delivery can elicit a local effect, or deliver drugs systemically without hepatic first pass metabolism. There are a number of emerging areas in intravaginal drug delivery, but the vagina is a challenging route of administration, due to the clearance mechanisms present which result in poor retention of dosage forms, and the potential for irritation and other adverse reactions. Gel formulations are desirable due to the ease of application, spreading and that they cause little to no discomfort to the patient. However, these dosage forms, in particular, are poorly retained and traditional gels typically have little control over drug release rates. This has led to a large number of studies on improving the retention of vaginal gels and modulating the controlled release of drugs from the gel matrix. This review outlines the anatomy and physiology of the vagina, focussing on areas relevant to drug delivery. Medical applications of vaginally administered medicines is then discussed, followed by an overview of polymeric gels in intravaginal drug delivery. The sensorial properties of intravaginal gels, and how these relate to user compliance are also summarised. Finally, some important barriers to marketing approval are described.en
dc.format.extent13
dc.format.extent1531173
dc.language.isoeng
dc.relation.ispartofJournal of Controlled Release
dc.subjectClinical trials
dc.subjectHIV PrEP
dc.subjectIn vitro models
dc.subjectMucoadhesion
dc.subjectRegulatory approval
dc.subjectThermogelling materials
dc.subjectPharmaceutical Science
dc.titlePolymeric gels for intravaginal drug deliveryen
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.description.statusPeer reviewed
dc.date.embargoedUntil2018-12-06
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85037531730&partnerID=8YFLogxK
rioxxterms.versionofrecord10.1016/j.jconrel.2017.12.004
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record